2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Transplantation, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Immunodeficiency, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

6074 Patients with transfusion-dependent thalassemia retain functional lymphocyte memory following single-agent busulfan myeloablative conditioning for betibeglogene autotemcel

Benjamin I. Philipson, MD, PhD, Jonathan Tedesco2, Rheanna Congdon, BS3, Elizabeth Worster, MSN, RN, CRNP4, Yi Qi, BA5, Sam Barnett Dubensky, PhD6, Nora Gibson, MD, MSCE7, Janet Kwiatkowski, MD, MSCE8, Timothy S. Olson, MD, PhD9, Laura A. Vella, MD, PhD, MSTR10
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Patients with transfusion-dependent thalassemia (TDT) endure single-agent busulfan myeloablative conditioning (Bu-MAC) to facilitate engraftment of CD34+-selected autologous gene-modified hematopoietic stem cells (GM-HSC) such as those in betibeglogene autotemcel (beti-cel). Despite Bu-MAC, patients with TDT have had few reported infections and had largely normal T, B, and NK cell counts by 3 months post beti-cel – strikingly faster than lymphocyte reconstitution post allogeneic HSC transplant (allo-HSCT) conditioning. However, the status of patients’ cellular and pathogen-specific immunologic memory after GM-HSCT remains unknown, leading many centers to continue strict allo-HSCT infection surveillance/prophylaxis and revaccination protocols. Therefore, we sought to define cellular adaptive immune reconstitution post-beti-cel, hypothesizing that patients with TDT retain functional immunologic memory amidst de novo lymphocyte production after beti-cel.

 

We performed deep immune cell profiling, recent thymic emigrant (RTE) quantification, and T cell function testing on peripheral blood mononuclear cell (PBMC) samples from children and young adults with TDT who received beti-cel post-FDA approval at the Children’s Hospital of Philadelphia (CHOP) and consented to the CHOP Bone Marrow Transplant Biorepository. Plasma and PBMCs were cryopreserved from peripheral blood samples collected prior to and 1, 2, 3, 4, 6, 8, and 12 months after beti-cel. We analyzed thawed patient PBMCs in parallel with aliquots of PBMCs from a healthy donor as a batch control. For deep immune cell profiling, we stained freshly thawed PBMCs with a 31-color spectral flow cytometry panel optimized for T and B cell differentiation. Separately, to assess pathogen-specific T cell function, PBMCs were rested for 6hrs before stimulation with a CMV peptide pool or anti-CD3/anti-CD28 antibody coated beads. After 16-18hrs of stimulation, T cell responses were assessed by activation-induced marker and cytokine expression.

 

Seven patients had PBMCs available for analysis. None had undergone prior splenectomy. None required red cell transfusions more than 44 days post-beti-cel with at least 6 months of follow-up for all patients. Mean Busulfan AUC received was 4683 µmol*min/L. Calculated counts of median primary lymphocyte subsets recovered to and persisted at or above near-normal levels for age for all patients by 2 months post-beti-cel: CD3+ = 715 (361-1510), CD3+, CD4+ = 412 (199-838), CD3+, CD8+ = 208 (145-572), CD19+ = 166 (145-354), NK cells = 71 (52-116).  

 

Five patients had cells available for longitudinal phenotyping. In CD4 T cells, memory phenotypes reconstituted evenly, varying within observed patient baseline distributions. CD8 T cell distributions shifted after beti-cel; early effector memory initially contracted while highly-differentiated effector memory expanded persistently. Memory B cells initially decreased, but rapidly rebounded with enrichment of switched-memory B cells. Naïve CD4 and CD8 T cells slowly decreased in number and frequency, with a nadir at 6 months post beti-cel. These reductions were accompanied by a rapid and sustained drop in both CD4 and CD8 RTEs. RTEs began increasing 6 months post beti-cel, followed by expansion of total naïve T cells. Naïve B cells decreased 1 month after beti-cel, but began rebounding one month later. Similar to RTEs, early transitional B cells dropped 1 month post beti-cel, but rapidly rebounded 1 month later ultimately accounting for a mean of nearly 1 in 4 circulating naïve B cells 3-to-4 months post beti-cel.

 

Five patients had cells available for T cell functional assessment. All 5 maintained CD8+ degranulation or CD4+ T cell cytokine production in response to bead activation above 40% of pre-conditioning responses at all timepoints post-beti-cel. In the 4 who were seropositive for CMV, 3 also displayed CMV-specific T cell responses before conditioning. All of these CMV-reactive patients had robust CMV-specific responses after two months post beti-cel.

 

We found that patients with TDT post beti-cel retained functional adaptive immune memory as well as naïve T cells while rapidly repopulating naive B cells de novo. In contrast to post-allo-HSCT immune reconstitution, the combination of retained functional memory lymphocytes and protective vaccine titers may sufficiently protect patients with TDT post-GM-HSCT to render prolonged isolation, latent viral prophylaxis, and full revaccination unnecessary.
Benjamin I. Philipson, MD, PhD: No relevant conflicts of interest to declare.